期刊
CARDIOVASCULAR DRUGS AND THERAPY
卷 37, 期 4, 页码 815-832出版社
SPRINGER
DOI: 10.1007/s10557-021-07306-8
关键词
Heart failure; Preserved ejection fraction; Pharmacotherapy; Clinical trials
While guidelines for heart failure with reduced ejection fraction (HFrEF) have led to improved survival, treatment options for heart failure with preserved ejection fraction (HFpEF) remain limited. This review summarizes recent clinical trial results for HFpEF and discusses the challenges in developing new pharmacotherapeutic options.
While guidelines for management of heart failure with reduced ejection fraction (HFrEF) are consensual and have led to improved survival, treatment options for heart failure with preserved ejection fraction (HFpEF) remain limited and aim primarily for symptom relief and improvement of quality of life. Due to the shortage of therapeutic options, several drugs have been investigated in multiple clinical trials. The majority of these trials have reported disappointing results and have suggested that HFpEF might not be as simply described by ejection fraction as previously though. In fact, HFpEF is a complex clinical syndrome with various comorbidities and overlapping distinct phenotypes that could benefit from personalized therapeutic approaches. This review summarizes the results from the most recent phase III clinical trials for HFpEF and the most promising drugs arising from phase II trials as well as the various challenges that are currently holding back the development of new pharmacotherapeutic options for these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据